1
|
Man F, Tang J, Swedrowska M, Forbes B, T M de Rosales R. Imaging drug delivery to the lungs: Methods and applications in oncology. Adv Drug Deliv Rev 2023; 192:114641. [PMID: 36509173 PMCID: PMC10227194 DOI: 10.1016/j.addr.2022.114641] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 11/25/2022] [Accepted: 11/26/2022] [Indexed: 12/14/2022]
Abstract
Direct delivery to the lung via inhalation is arguably one of the most logical approaches to treat lung cancer using drugs. However, despite significant efforts and investment in this area, this strategy has not progressed in clinical trials. Imaging drug delivery is a powerful tool to understand and develop novel drug delivery strategies. In this review we focus on imaging studies of drug delivery by the inhalation route, to provide a broad overview of the field to date and attempt to better understand the complexities of this route of administration and the significant barriers that it faces, as well as its advantages. We start with a discussion of the specific challenges for drug delivery to the lung via inhalation. We focus on the barriers that have prevented progress of this approach in oncology, as well as the most recent developments in this area. This is followed by a comprehensive overview of the different imaging modalities that are relevant to lung drug delivery, including nuclear imaging, X-ray imaging, magnetic resonance imaging, optical imaging and mass spectrometry imaging. For each of these modalities, examples from the literature where these techniques have been explored are provided. Finally the different applications of these technologies in oncology are discussed, focusing separately on small molecules and nanomedicines. We hope that this comprehensive review will be informative to the field and will guide the future preclinical and clinical development of this promising drug delivery strategy to maximise its therapeutic potential.
Collapse
Affiliation(s)
- Francis Man
- School of Cancer & Pharmaceutical Sciences, King's College London, London, SE1 9NH, United Kingdom
| | - Jie Tang
- School of Biomedical Engineering & Imaging Sciences, King's College London, London SE1 7EH, United Kingdom
| | - Magda Swedrowska
- School of Cancer & Pharmaceutical Sciences, King's College London, London, SE1 9NH, United Kingdom
| | - Ben Forbes
- School of Cancer & Pharmaceutical Sciences, King's College London, London, SE1 9NH, United Kingdom
| | - Rafael T M de Rosales
- School of Biomedical Engineering & Imaging Sciences, King's College London, London SE1 7EH, United Kingdom.
| |
Collapse
|
2
|
Abstract
Over the past 3 decades, monoclonal antibodies and their related derivatives, including recently approved antibody-drug conjugates, conquered a central role in cancer therapy because of their contribution to improve survival, time to progression and quality of life of patients compared to chemotherapy protocols. This review summarizes information on approved original and biosimilar products, as well as investigational antibody-based therapeutics, targeting ErbB2. This target has been selected as a paradigmatic example because of its relevant role in sustaining the malignancy of major cancer diseases including, breast, gastric and other chemotherapy-resistant solid tumors. This work analyzes the drivers affecting research and development of next-generation anti-ErbB2 immunotherapeutics, taking into account unmet medical needs and pharmacoeconomic issues related to sustainability. The analysis may help with the design of future research and development strategies.
Collapse
Affiliation(s)
- Rita De Santis
- Biotechnology Research and Development, Alfasigma SpA, Rome, Italy
| |
Collapse
|
3
|
Matthews AA, Ee PLR, Ge R. Developing inhaled protein therapeutics for lung diseases. MOLECULAR BIOMEDICINE 2020; 1:11. [PMID: 34765995 PMCID: PMC7595758 DOI: 10.1186/s43556-020-00014-z] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Accepted: 10/15/2020] [Indexed: 12/28/2022] Open
Abstract
Biologic therapeutics such as protein/polypeptide drugs are conventionally administered systemically via intravenous injection for the treatment of diseases including lung diseases, although this approach leads to low target site accumulation and the potential risk for systemic side effects. In comparison, topical delivery of protein drugs to the lung via inhalation is deemed to be a more effective approach for lung diseases, as proteins would directly reach the target in the lung while exhibiting poor diffusion into the systemic circulation, leading to higher lung drug retention and efficacy while minimising toxicity to other organs. This review examines the important considerations and challenges in designing an inhaled protein therapeutics for local lung delivery: the choice of inhalation device, structural changes affecting drug deposition in diseased lungs, clearance mechanisms affecting an inhaled protein drug’s lung accumulation, protein stability, and immunogenicity. Possible approaches to overcoming these issues will also be discussed.
Collapse
|
4
|
Vesci L, Carollo V, Rosi A, De Santis R. Therapeutic efficacy of intra-tumor AvidinOX and low systemic dose biotinylated cetuximab, with and without cisplatin, in an orthotopic model of head and neck cancer. Oncol Lett 2019; 17:3529-3536. [PMID: 30867794 DOI: 10.3892/ol.2019.10003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Accepted: 01/17/2019] [Indexed: 11/05/2022] Open
Abstract
In a previous study, the efficacy of low intraperitoneal doses of biotinylated cetuximab (bCet) in mice with subcutaneous tumor xenografts of human head and neck cancer (HNC) treated intra-tumors with AvidinOX was reported. Taking into account that the current standard treatment for HNC is the combination of cetuximab and cisplatin, the present study investigated the activity of AvidinOX-targeted bCet with and without cisplatin in an orthotopic model. The results confirmed that administration of intra-tumor AvidinOX makes an otherwise inactive dose of bCet effective in reducing tumor growth, and the addition of a low dose of cisplatin further improved tumor growth inhibition. Supporting the in vivo data, immunohistochemical staining of tumor masses from mice treated with AvidinOX, bCet and cisplatin exhibited the highest tumor cell damage and the lowest angiogenic activity among all treatment groups, measured as the number of γ-H2A.X and cleaved caspase-3-positive cells, and vascular endothelial growth factor-C and platelet and endothelial cell adhesion molecule 1-positive cells, respectively. AvidinOX is currently under clinical investigation to assess its use in delivering radioactive biotin to inoperable tumor lesions (ClinicalTrials.gov: NCT02053324 and NCT03188328). The present study further supported the potential clinical use of AvidinOX to target low bCet doses to inoperable tumor lesions, with or without an additional low dose of cisplatin. Since low doses of highly expensive monoclonal antibodies become effective with AvidinOX and low dose cisplatin, such therapies promise to be cheaper and less toxic than current treatments.
Collapse
Affiliation(s)
- Loredana Vesci
- Biotechnology R&D, Alfasigma S.p.A., Pomezia, I-00071 Rome, Italy
| | | | - Antonio Rosi
- Biotechnology R&D, Alfasigma S.p.A., Pomezia, I-00071 Rome, Italy
| | - Rita De Santis
- Biotechnology R&D, Alfasigma S.p.A., Pomezia, I-00071 Rome, Italy
| |
Collapse
|
5
|
Minenkova O, Vesci L, De Santis R, Santapaola D, Cincinelli R, Musso L, Dallavalle S, Giannini G. Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative. Bioorg Med Chem Lett 2018; 28:3312-3314. [PMID: 30243588 DOI: 10.1016/j.bmcl.2018.09.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Revised: 09/07/2018] [Accepted: 09/13/2018] [Indexed: 10/28/2022]
Abstract
Oxidized form of avidin, named AvidinOX, provides stable fixation of biotinylated molecules in tissues thus representing a breakthrough in topical treatment of cancer. AvidinOX proved to be a stable receptor for radiolabeled biotin, biotinylated antibodies and cells. In order to expand applicability of the AvidinOX-based delivery platform, in the present study we investigated the possibility to hold biotinylated chemotherapeutics in AvidinOX-treated sites. A novel biotinylated gimatecan-derived camptothecin, coded ST8161AA1, was injected at suboptimal doses into human tumors xenografted in mice alone or pre-complexed to AvidinOX. Significantly higher growth inhibition was observed when the drug was anchored to AvidinOX suggesting the potential utility of this delivery modality for the local treatment of inoperable tumors.
Collapse
Affiliation(s)
- Olga Minenkova
- Biotechnology, Research & Development, Alfasigma SpA, 00071 Pomezia (RM), Italy
| | - Loredana Vesci
- Biotechnology, Research & Development, Alfasigma SpA, 00071 Pomezia (RM), Italy
| | - Rita De Santis
- Biotechnology, Research & Development, Alfasigma SpA, 00071 Pomezia (RM), Italy
| | - Daniela Santapaola
- Biotechnology, Research & Development, Alfasigma SpA, 00071 Pomezia (RM), Italy
| | - Raffaella Cincinelli
- DeFENS - Department of Food, Environmental and Nutritional Sciences, University of Milan, 20133 Milan, Italy
| | - Loana Musso
- DeFENS - Department of Food, Environmental and Nutritional Sciences, University of Milan, 20133 Milan, Italy
| | - Sabrina Dallavalle
- DeFENS - Department of Food, Environmental and Nutritional Sciences, University of Milan, 20133 Milan, Italy
| | - Giuseppe Giannini
- Biotechnology, Research & Development, Alfasigma SpA, 00071 Pomezia (RM), Italy.
| |
Collapse
|
6
|
Characterization of therapeutic protein AvidinOX by an integrated analytical approach. Anal Bioanal Chem 2017; 410:553-564. [PMID: 29167933 DOI: 10.1007/s00216-017-0754-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Revised: 10/18/2017] [Accepted: 11/07/2017] [Indexed: 10/18/2022]
Abstract
AvidinOX, the oxidized derivative of Avidin, is a chemically modified glycoprotein, being currently under clinical investigation for targeted delivery of radioactive biotin to inoperable tumors. AvidinOX is produced by 4-hydroxyazobenzene-2-carboxylic acid (HABA)-assisted sodium periodate oxidation of Avidin. The peculiar property of the periodate-generated glycol-split carbohydrate moieties to form Schiff's bases with amino groups of the tissue proteins allows to achieve a tissue half-life of 2 weeks compared to 2 h of native Avidin. Carbohydrate oxidation, along with possible minor amino acid modifications, introduces additional microheterogeneity in the glycoprotein structure, making its characterization even more demanding than for native glycoproteins. Aiming at the elucidation of the effects of oxidation conditions on the AvidinOX protein backbone and sugars, this microheterogeneous glycoprotein derivative was characterized for the first time using a combination of different analytical methods, including colorimetric methods, mass spectrometry, hollow-fiber flow field-flow fractionation with UV and multi-angle laser scattering detection (HF5-UV-MALS), and NMR. The proposed integrated approach reveals structural features of AvidinOX relevant for its biological activity, e.g., oxidized sites within both carbohydrate moieties and protein backbone and conformational stability, and will be considered as an analytical tool for AvidinOX industrial preparations. It is worth noting that this study enriches also the structural data of native Avidin published up-to-date (e.g., glycan structure and distribution, peptide fingerprint, etc.). Graphical abstract Scheme of phenylacetic hydrazide/MALDI-TOF approach for quantification of aldehydes in AvidinOX based on the determination of the number of hydrazone adducts between hydrazide reagent and aldehyde groups of protein.
Collapse
|
7
|
Milazzo FM, Anastasi AM, Chiapparino C, Rosi A, Leoni B, Vesci L, Petronzelli F, De Santis R. AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies. Oncotarget 2017; 8:22590-22605. [PMID: 28186982 PMCID: PMC5410247 DOI: 10.18632/oncotarget.15145] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2016] [Accepted: 01/25/2017] [Indexed: 01/22/2023] Open
Abstract
The oxidized version of Avidin, known as AvidinOX, was previously shown to link to tissue proteins upon injection or nebulization, thus becoming a stable receptor for biotinylated therapeutics. AvidinOX is currently under clinical investigation to target radioactive biotin to inoperable tumor lesions (ClinicalTrials.gov NCT02053324). Presently, we show that the anti-ErbB2 monoclonal antibodies Trastuzumab and Pertuzumab can be chemically biotinylated while maintaining their biochemical and biological properties. By using several and diverse experimental conditions, we show that when AvidinOX is conjugated to tumor cells, low antibody concentrations of biotinylated Trastuzumab (bTrast) or Pertuzumab (bPert) prevent internalization of ErbB2, induce endoplasmic reticulum stress, cell cycle arrest and apoptosis leading to inhibition of proliferation and ErbB2 signaling. Moreover, we found that the treatment is able to induce down-modulation of ErbB2 thus bypassing the known resistance of this receptor to degradation. Interestingly, we show that AvidinOX anchorage is a way to counteract agonistic activities of Trastuzumab and Pertuzumab. Present data are in agreement with previous observations from our group indicating that the engagement of the Epidermal Growth Factor Receptor (EGFR) by AvidinOX-bound biotinylated Cetuximab or Panitumumab, leads to potent tumor inhibition both in vitro and in animal models. All results taken together encourage further investigation of AvidinOX-based treatments with biotinylated antibodies directed to the members of the EGFR family.
Collapse
Affiliation(s)
| | - Anna Maria Anastasi
- Biotech Products, Research and Development, Sigma-Tau SpA, 00071 Pomezia (Rome), Italy
| | - Caterina Chiapparino
- Biotech Products, Research and Development, Sigma-Tau SpA, 00071 Pomezia (Rome), Italy
| | - Antonio Rosi
- Biotech Products, Research and Development, Sigma-Tau SpA, 00071 Pomezia (Rome), Italy
| | - Barbara Leoni
- Biotech Products, Research and Development, Sigma-Tau SpA, 00071 Pomezia (Rome), Italy
| | - Loredana Vesci
- Biotech Products, Research and Development, Sigma-Tau SpA, 00071 Pomezia (Rome), Italy
| | - Fiorella Petronzelli
- Biotech Products, Research and Development, Sigma-Tau SpA, 00071 Pomezia (Rome), Italy
| | - Rita De Santis
- Biotech Products, Research and Development, Sigma-Tau SpA, 00071 Pomezia (Rome), Italy
| |
Collapse
|
8
|
Vesci L, Milazzo FM, Anastasi AM, Petronzelli F, Chiapparino C, Carollo V, Roscilli G, Marra E, Luberto L, Aurisicchio L, Pacello ML, Spagnoli LG, De Santis R. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer. Oncotarget 2016; 7:914-28. [PMID: 26575422 PMCID: PMC4808042 DOI: 10.18632/oncotarget.6089] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 10/26/2015] [Indexed: 12/15/2022] Open
Abstract
For locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC), the current clinical use of Cetuximab in chemo/radiotherapy protocols is often associated to severe systemic toxicity. Here we report in vitro data in human FaDu pharynx SCC cells, showing that inactive concentrations of biotinylated Cetuximab (bCet) become active upon anchorage to AvidinOX on the surface of tumor cells. AvidinOX-anchored bCet induces apoptosis and DNA damage as well as specific inhibition of signaling, degradation and abrogation of nuclear translocation of EGFR. In the mouse model of FaDu cancer, we show that intra-tumor injection of AvidinOX allows anti-tumor activity of an otherwise inactive, intraperitoneally delivered, low dose bCet. Consistently with in vitro data, in vivo tumor inhibition is associated to induction of apoptosis, DNA damage and reduced angiogenesis. AvidinOX is under clinical investigation for delivering radioactive biotin to inoperable tumors (ClinicalTrials.gov NCT02053324) and present data support its use for the local treatment of HNSCC in combination with systemic administration of low dose bCet.
Collapse
Affiliation(s)
- Loredana Vesci
- Biotechnology, Research & Development, Sigma-Tau SpA, 00071 Pomezia, Rome, Italy
| | | | - Anna Maria Anastasi
- Biotechnology, Research & Development, Sigma-Tau SpA, 00071 Pomezia, Rome, Italy
| | - Fiorella Petronzelli
- Biotechnology, Research & Development, Sigma-Tau SpA, 00071 Pomezia, Rome, Italy
| | - Caterina Chiapparino
- Biotechnology, Research & Development, Sigma-Tau SpA, 00071 Pomezia, Rome, Italy
| | - Valeria Carollo
- Tissue Macro Array Lab, University of Tor Vergata, via della Ricerca Scientifica, 00133, Rome, Italy
| | | | | | | | | | | | - Luigi Giusto Spagnoli
- Tissue Macro Array Lab, University of Tor Vergata, via della Ricerca Scientifica, 00133, Rome, Italy
| | - Rita De Santis
- Biotechnology, Research & Development, Sigma-Tau SpA, 00071 Pomezia, Rome, Italy
| |
Collapse
|
9
|
Desoubeaux G, Reichert JM, Sleeman M, Reckamp KL, Ryffel B, Adamczewski JP, Sweeney TD, Vanbever R, Diot P, Owen CA, Page C, Lerondel S, Le Pape A, Heuze-Vourc'h N. Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France. MAbs 2016; 8:999-1009. [PMID: 27266390 PMCID: PMC4968091 DOI: 10.1080/19420862.2016.1196521] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence “MAbImprove,” the GDR 3260 “Antibodies and therapeutic targeting,” and the Grant Research program ARD2020 “Biotherapeutics” invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 – April 1, 2016 in Tours, France.
Collapse
Affiliation(s)
- Guillaume Desoubeaux
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.,c Centre Hospitalo-Universitaire de Tours , Tours , France
| | - Janice M Reichert
- d The Antibody Society , Framingham , MA , USA.,e Reichert Biotechnology Consulting LLC , Framingham MA , USA
| | | | - Karen L Reckamp
- g City of Hope, Comprehensive Cancer Center , Duarte , CA , USA
| | - Bernhard Ryffel
- h Université d'Orléans , Orléans , France.,i University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM) , Cape Town , South Africa
| | | | | | - Rita Vanbever
- l Université Catholique de Louvain, Louvain Drug Research Institute , Brussels , Belgium
| | - Patrice Diot
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.,c Centre Hospitalo-Universitaire de Tours , Tours , France
| | - Caroline A Owen
- m Harvard Medical School, Brigham and Women's Hospital , Boston , MA , USA.,n Lovelace Respiratory Research Institute , Albuquerque , NM , USA
| | - Clive Page
- o King's College, Sackler Institute of Pulmonary Pharmacology , London , UK
| | | | - Alain Le Pape
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.,p PHENOMIN-TAAM CNRS, CIPA , Orléans , France
| | - Nathalie Heuze-Vourc'h
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France
| |
Collapse
|
10
|
Salova AV, Belyaeva TN, Leontieva EA, Zlobina MV, Kharchenko MV, Kornilova ES. Quantum dots implementation as a label for analysis of early stages of EGF receptor endocytosis: a comparative study on cultured cells. Oncotarget 2016; 7:6029-47. [PMID: 26716513 PMCID: PMC4868738 DOI: 10.18632/oncotarget.6720] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2015] [Accepted: 11/25/2015] [Indexed: 12/16/2022] Open
Abstract
EGF complexed to fluorescent photostable quantum dots by biotin-streptavidin system (bEGF-savQD) is attractive for both the basic research and therapeutic application such as targeted drug delivery in EGF-receptor (EGFR) expressing cancers. However, compared to native EGF, the large size of QD and its quasi-multivalency can have unpredictable effects on EGFR endocytosis changing the internalization portal and/or endosomal processing tightly bound to EGF signaling. We have found that bEGF-savQDs enter HeLa cells via the temperature-dependent clathrin-mediated EGF-receptor-specific pathway characteristic for native EGF. We also found that EGF-to-QD concentration ratios used for the complex preparation and the level of EGF receptor expression affect the number and integral densities of the formed endosomes. So, at EGF-to-QD ratio from 4:1 to 12:1 (at nanomolar bEGF concentrations) on average 100 bright endosomes per HeLa cell were formed 15 min after the complex addition, while 1:1 ratio resulted in formation of very few dim endosomes. However, in A431 cells overexpressing EGFR 1:1 ratio was effective. Using dynamin inhibition and Na-acidic washout we showed that bEGF-savQDs bind surface receptors and enter clathrin-coated pits slower than the same ligands without QD. Yet, the bEGF-savQD demonstrated similar to native EGF and bEGF-savCy3 co-localization dynamics with tethering protein EEA1 and HRS, the key component of sorting ESCRT0 complex. In conclusion, our comparative study reveals that in respect to entrapment into coated pits, endosomal recruitment, endosome fusions, and the initial steps of endosomal maturation, bEGF-savQD behaves like native EGF and QD implementation does not affect these important events.
Collapse
Affiliation(s)
- Anna V. Salova
- Institute of Cytology of the Russian Academy of Sciences, St. Petersburg, Russia
| | - Tatiana N. Belyaeva
- Institute of Cytology of the Russian Academy of Sciences, St. Petersburg, Russia
| | | | - Maria V. Zlobina
- Institute of Cytology of the Russian Academy of Sciences, St. Petersburg, Russia
- Central European Institute of Technology, Brno, Czech Republic
| | | | - Elena S. Kornilova
- Institute of Cytology of the Russian Academy of Sciences, St. Petersburg, Russia
- Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia
- St. Petersburg State University, St. Petersburg, Russia
| |
Collapse
|
11
|
Albertoni C, Leoni B, Rosi A, D'Alessio V, Carollo V, Spagnoli LG, van Echteld C, De Santis R. Radionuclide Therapy of Unresectable Tumors with AvidinOX and (90)Y-biotinDOTA: Tongue Cancer Paradigm. Cancer Biother Radiopharm 2015; 30:291-8. [PMID: 26167947 PMCID: PMC4575534 DOI: 10.1089/cbr.2015.1837] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Local treatment of unresectable tumors is challenging, particularly with radioactivity. Current practice relies on external beam irradiation or on a variety of medical devices for brachytherapy. Both approaches proved useful in controlling tumor growth, but are characterized by poor compliance of the patient, significant side-effects, high costs, and technological complexity, which hamper widespread use. The authors recently described a novel form of radionuclide therapy based on the oxidized form of avidin that, chemically reacting with tissue proteins, can secure radioactive biotin within the injected tissue, either when precomplexed or when taken from the blood stream after intravenous administration. AvidinOX-pretargeted 177Lu-biotinDOTA (177Lu-ST2210) is currently under clinical investigation for the treatment of liver oligometastases from colorectal cancer (clinicaltrials.gov/NCT02053324). In the present work, the authors show that injected AvidinOX can link tissues of various natures such as prostate, kidney, breast, or brain and can react by contact with scraped tissues such as skin or urinary bladder. AvidinOX injected into human OSC19 tongue cancer masses orthotopically transplanted in nude mice takes up intravenously administered 90Y-ST2210, which exerts significant antitumor activity, while preserving the integrity and functionality of the tongue. Present data confirm that AvidinOX-based radionuclide therapy is an innovative and promising approach for the local treatment of inoperable tumors.
Collapse
Affiliation(s)
| | - Barbara Leoni
- 1 Department of Biotechnology, Sigma-Tau SpA , Pomezia, Rome, Italy
| | - Antonio Rosi
- 1 Department of Biotechnology, Sigma-Tau SpA , Pomezia, Rome, Italy
| | | | - Valeria Carollo
- 2 Department of Histopathology, Histo-Cyto Service , Rome, Italy
| | | | | | - Rita De Santis
- 1 Department of Biotechnology, Sigma-Tau SpA , Pomezia, Rome, Italy
| |
Collapse
|